102340Clinical Management of COPD at point-of-careClosedLaunchpadInnovate UKGlyconics has developed a new device for rapid, cost-effective diagnosis of Chronic Obstructive Pulmonary Disease (COPD) using sputum samples. The technology analyses the presence of specific markers in sputum that are characteristic of COPD. In addition the technology is able to detect the onset of an exacerbation episode earlier than the current methods meaning that patients can be treated earlier than is currently possible. COPD is a disease with a growing clinical burden and one of the main challenges is the high rate of hospitalisation arising during disease exacerbation. The ability to spot exacerbation earlier means that COPD patients are less likely to need to be hospitalised. This project is intended to complete prospective clinical trials to confirm the clinical value of the technology. In addition it will allow Glyconics to set up its assembly pipeline so there will be no delay in providing the technology to the NHS assuming that the clinical data is satisfactory.